Briumvi

• BRIUMVI™(Ublituximab) is an intravenous injection treatment for relapsing forms of multiple sclerosis (MS) in adults.
• It is a CD20-directed cytolytic antibody that was first approved in the U.S. in 2022.

Screening

• Before using BRIUMVI, patients must be screened for hepatitis B virus and have a quantitative serum immunoglobulin screening.
• They should also pre-medicate with methylprednisolone and an antihistamine before each infusion.

Dosage

• The BRIUMVI dosage is 150 mg for the first infusion, 450 mg for the second infusion two weeks later, and 450 mg for subsequent infusions every 24 weeks.
• BRIUMVI should be diluted with 0.9% Sodium Chloride Injection before administration, and patients should be monitored closely during and after the first two infusions.

Contraindications

• BRIUMVI is contraindicated for those with active hepatitis B virus infection or a history of life-threatening infusion reactions to the treatment.
• Infusion reactions and infections, including serious and potentially fatal infections, may occur during treatment.
• Patients should avoid live-attenuated or live vaccines while on BRIUMVI and for some time after stopping it.
• The level of immunoglobulins should also be monitored, and BRIUMVI may be discontinued if serious opportunistic or recurrent infections occur.
• BRIUMVI can also cause fetal harm, so females of reproductive potential should be advised to use effective contraception during treatment and for at least 6 months after stopping it.

Side effects

Common adverse reactions include infusion reactions and upper respiratory tract infections.

Briumvi Resources
Latest articles Most recent articles Ongoing trials	Wikipedia